Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Golnerminogene pradenovec

Drug Profile

Golnerminogene pradenovec

Alternative Names: ADgvEGR.TNF.11D; TNF-α gene therapy - GenVec; TNFerade; Tumour necrosis factor-alpha gene therapy - GenVec

Latest Information Update: 29 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei
  • Developer GenVec; National Cancer Institute (USA)
  • Class Antineoplastics; Cytokine genes; Gene therapies
  • Mechanism of Action Gene transference; Tumour necrosis factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Malignant melanoma; Oesophageal cancer; Pancreatic cancer; Prostate cancer; Sarcoma

Most Recent Events

  • 16 Jun 2017 GenVec was acquired by Intrexon Corporation
  • 04 Sep 2013 Golnerminogene pradenovec is available for licensing as of 04 Sep 2013. http://www.genvec.com/
  • 02 Nov 2010 GenVec receives Qualifying Therapeutic Discovery Project grant from the US Government for Golnerminogene pradenovec development in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top